Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Rhea-AI Summary
Fortress Biotech (Nasdaq: FBIO) announced that Chairman, President and CEO Lindsay A. Rosenwald, M.D., will join a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on Wednesday, May 20, 2026, starting at 12:20 p.m. ET. Conference registration is available via A.G.P.’s online registration link.
Positive
- None.
Negative
- None.
News Market Reaction – FBIO
In the May 18 session, FBIO gained 2.90%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.3% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 2026 earnings | Positive | +4.8% | Strong Q1 profit, higher cash, FDA approval and PRV sale benefits. |
| May 13 | Subsidiary earnings | Positive | +3.1% | Journey revenue growth, improved losses, positive EBITDA and cash build. |
| May 06 | Earnings date notice | Neutral | -5.9% | Announcement of upcoming Journey Q1 results and conference call timing. |
| May 04 | Conference participation | Neutral | +2.1% | Fortress CEO scheduled for virtual royalty company conference fireside chat. |
| Apr 21 | Access expansion | Positive | -3.9% | Journey expands Emrosi access via third major GPO and broader coverage. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent FBIO-related and affiliate news often sees price moves that sometimes diverge from clearly positive operational updates.
Over the past month, Fortress and its affiliate Journey Medical reported several significant updates. On May 14, 2026, Fortress posted strong Q1 results with net income of $108.4 million and higher cash, which coincided with a 4.78% gain. Journey’s Q1 results on May 13 also saw a positive reaction. Earlier, a simple earnings-date notice for Journey on May 6 drew a negative move, while a May 4 Fortress conference participation headline had a modestly positive impact. Journey’s April 21 GPO contract news saw a negative reaction, highlighting that price often underreacts or diverges from seemingly positive fundamentals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 12:20pm ET.
To register for the conference, visit the A.G.P. Registration Link.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.
Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
